JP2021511365A5 - - Google Patents
Info
- Publication number
- JP2021511365A5 JP2021511365A5 JP2020541352A JP2020541352A JP2021511365A5 JP 2021511365 A5 JP2021511365 A5 JP 2021511365A5 JP 2020541352 A JP2020541352 A JP 2020541352A JP 2020541352 A JP2020541352 A JP 2020541352A JP 2021511365 A5 JP2021511365 A5 JP 2021511365A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- day
- htp
- combination pharmaceutical
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023119314A JP2023153871A (ja) | 2018-01-29 | 2023-07-21 | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623073P | 2018-01-29 | 2018-01-29 | |
| US62/623,073 | 2018-01-29 | ||
| US201862743816P | 2018-10-10 | 2018-10-10 | |
| US62/743,816 | 2018-10-10 | ||
| PCT/US2019/015391 WO2019148087A1 (en) | 2018-01-29 | 2019-01-28 | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119314A Division JP2023153871A (ja) | 2018-01-29 | 2023-07-21 | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511365A JP2021511365A (ja) | 2021-05-06 |
| JP2021511365A5 true JP2021511365A5 (enExample) | 2022-01-25 |
| JP7758320B2 JP7758320B2 (ja) | 2025-10-22 |
Family
ID=67395723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541352A Active JP7758320B2 (ja) | 2018-01-29 | 2019-01-28 | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 |
| JP2023119314A Withdrawn JP2023153871A (ja) | 2018-01-29 | 2023-07-21 | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119314A Withdrawn JP2023153871A (ja) | 2018-01-29 | 2023-07-21 | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11337963B2 (enExample) |
| EP (1) | EP3746058B1 (enExample) |
| JP (2) | JP7758320B2 (enExample) |
| KR (2) | KR20200116110A (enExample) |
| CN (1) | CN111902137A (enExample) |
| AU (1) | AU2019211458B2 (enExample) |
| BR (1) | BR112020015068A2 (enExample) |
| ES (1) | ES2948788T3 (enExample) |
| IL (1) | IL276059B2 (enExample) |
| MX (1) | MX2020007760A (enExample) |
| MY (1) | MY209656A (enExample) |
| RU (1) | RU2020125170A (enExample) |
| SG (1) | SG11202007178VA (enExample) |
| WO (1) | WO2019148087A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12409163B2 (en) * | 2021-07-30 | 2025-09-09 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-HTP) exposure |
| JP2024528125A (ja) | 2021-07-30 | 2024-07-26 | エヴェクシア セラピューティクス， インク． | ５－ヒドロキシトリプトファン胃内滞留性剤形 |
| US11779567B2 (en) | 2021-10-14 | 2023-10-10 | Evecxia Therapeutics, Inc. | Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
| DE102022103658A1 (de) * | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
| WO2024148354A1 (en) | 2023-01-06 | 2024-07-11 | Evecxia Therapeutics, Inc. | A method of enhancing 5-hydroxytryptophan (5-htp) exposure |
| CN119074695A (zh) * | 2024-08-29 | 2024-12-06 | 江南大学 | 一种可提高脑内5-ht水平的口服缓释制剂及其在改善失眠中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658038A (en) | 1982-10-07 | 1987-04-14 | Research Foundation For Mental Hygiene, Inc. | N-acylated 5-hydroxytryptophan amide derivatives |
| FR2654931B1 (fr) * | 1989-11-24 | 1993-08-27 | Trouillas Paul | Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa. |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
| US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| AU2003293423A1 (en) | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| EP1746985A4 (en) * | 2004-05-21 | 2010-08-11 | Univ Duke | METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS |
| US20070213370A1 (en) * | 2005-11-18 | 2007-09-13 | H. Lundbeck A/S | 5-HTP Combination Therapy |
| US8969400B2 (en) | 2007-10-01 | 2015-03-03 | Duke University | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound |
| KR101687781B1 (ko) | 2008-08-15 | 2016-12-20 | 데포메드 인코퍼레이티드 | Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물 |
| KR20120115991A (ko) * | 2010-02-05 | 2012-10-19 | 포스파제닉스 리미티드 | 담체 조성물 |
| EP2629615B1 (en) | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| CN103554005A (zh) | 2013-11-22 | 2014-02-05 | 长沙理工大学 | 一种左旋5-羟基色氨酸的简便合成新方法 |
-
2019
- 2019-01-28 MY MYPI2020003883A patent/MY209656A/en unknown
- 2019-01-28 EP EP19743636.3A patent/EP3746058B1/en active Active
- 2019-01-28 WO PCT/US2019/015391 patent/WO2019148087A1/en not_active Ceased
- 2019-01-28 MX MX2020007760A patent/MX2020007760A/es unknown
- 2019-01-28 IL IL276059A patent/IL276059B2/en unknown
- 2019-01-28 SG SG11202007178VA patent/SG11202007178VA/en unknown
- 2019-01-28 AU AU2019211458A patent/AU2019211458B2/en active Active
- 2019-01-28 KR KR1020207024221A patent/KR20200116110A/ko not_active Ceased
- 2019-01-28 JP JP2020541352A patent/JP7758320B2/ja active Active
- 2019-01-28 KR KR1020257004583A patent/KR20250025043A/ko active Pending
- 2019-01-28 BR BR112020015068-1A patent/BR112020015068A2/pt unknown
- 2019-01-28 ES ES19743636T patent/ES2948788T3/es active Active
- 2019-01-28 RU RU2020125170A patent/RU2020125170A/ru unknown
- 2019-01-28 US US15/733,423 patent/US11337963B2/en active Active
- 2019-01-28 CN CN201980021717.5A patent/CN111902137A/zh active Pending
-
2023
- 2023-07-21 JP JP2023119314A patent/JP2023153871A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3463323B1 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| JP2025024102A (ja) | 神経障害および神経障害の処置方法 | |
| KR20250114110A (ko) | 약물 활성의 조절제로서의 부프로피온 | |
| CA2825428C (en) | Compositions and methods for treating depression | |
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| JP2014198723A5 (enExample) | ||
| US20140315910A1 (en) | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | |
| JP2014507475A (ja) | シクロベンザプリンを使用してうつ病を処置するための方法および組成物 | |
| CN101257907A (zh) | 左旋佐匹克隆和抗抑郁剂的组合 | |
| CN104013638B (zh) | 当药黄素及其衍生物的用途 | |
| JP2011504885A (ja) | 棗の環状アデノシン一リン酸から調製された抗うつ薬 | |
| JP2025504984A5 (enExample) | ||
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| AU2022202285A1 (en) | Compositions and methods for treating depression | |
| RU2802516C1 (ru) | Комбинированная терапия циклосерином и литием для лечения депрессии | |
| CN102949332A (zh) | 含有西酞普兰的抗抑郁口服缓、控释药用组合物 | |
| CN114786668B (zh) | 用于治疗抑郁症的环丝氨酸和锂的组合疗法 | |
| AU2018371628B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| CN120051276A (zh) | 减少对神经精神病学治疗的身体依赖性的方法 | |
| TW200817003A (en) | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor | |
| CA3042699C (en) | Compositions and methods for treating depression | |
| JP2024529009A5 (enExample) | ||
| KR20140069120A (ko) | S1p 수용체 조절제를 포함하는 조합물 | |
| JP2018509436A (ja) | ８−シクロプロピル−３−［２−（３−フルオロフェニル）エチル］−７，８−ジヒドロ−３ｈ−［１，３］オキサジノ［６，５−ｇ］［１，２，３］ベンゾトリアジン−４，９−ジオンと抗うつ剤との新規な組み合わせ、及びそれを含有する医薬組成物 |